Sign in
BNTC Stock Price, Chart, Stats & News
Benitec Biopharma Inc.
Save
Benitec Biopharma Inc. (BNTC) does not currently pay a dividend.
437.16M
Market cap
–
Current P/E
–
Forward P/E
BNTC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -11.87% |
Operating margin | -9090.65% |
Pretax margin | -8327.88% |
Net margin | -8327.88% |
Effective tax rate | – |
ROA | -24.28% |
ROE | -38.92% |
D/E | 0.01x |
Interest coverage ratio | – |
BNTC valuation
P/E | – |
P/S | 484.82x |
P/B | 2.52x |
P/CF | -25.19x |
P/FCF | -14.37x |
P/OCF | -25.19x |
PEG | -1.72x |
EV multiple | -8.91x |
About
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
Similar securities
Based on sector and market capitalization
Report issue